Teva announces launch of generic Prometrium® Capsules in the US
Posted: 2 March 2012 | | No comments yet
Teva Pharmaceutical Industries Ltd. announced the commercial launch of Progesterone Capsules…
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories’ Prometrium® Capsules.
The brand product had annual sales of approximately $197 million in the United States, based on IMS sales data.
The product is indicated for the treatment of secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus.
